NYSE:EW - Edwards Lifesciences Stock Price, Price Target & More

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences shares split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were distributed to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences announced that its Board of Directors has approved a share buyback plan on Thursday, December 7th 2017, which allows the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its stock is undervalued.

Edwards Lifesciences Corp (NYSE:EW) released its quarterly earnings data on Tuesday, April, 24th. The medical research company reported $1.22 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.11 by $0.11. The medical research company had revenue of $938 million for the quarter, compared to analysts' expectations of $936.69 million. Edwards Lifesciences had a net margin of 17.36% and a return on equity of 28.60%. The business's revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.94 earnings per share. View Edwards Lifesciences' Earnings History.

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Edwards Lifesciences.

Edwards Lifesciences issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $4.50-$4.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.53. The company issued revenue guidance of $3.5-$3.9 billion, compared to the consensus revenue estimate of $3.85 billion.Edwards Lifesciences also updated its Q2 guidance to $1.05-$1.15 EPS.

18 brokers have issued 12-month price objectives for Edwards Lifesciences' shares. Their forecasts range from $115.00 to $180.00. On average, they expect Edwards Lifesciences' share price to reach $149.3333 in the next twelve months. View Analyst Ratings for Edwards Lifesciences.

Edwards Lifesciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 5,610,181 shares, an increase of 62.3% from the April 30th total of 3,456,057 shares. Based on an average daily trading volume, of 1,266,171 shares, the days-to-cover ratio is currently 4.4 days. Approximately 2.7% of the company's shares are short sold. View Edwards Lifesciences' Current Options Chain.

Some companies that are related to Edwards Lifesciences include Intuitive Surgical (ISRG), Align Technology (ALGN), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), Steris (STE), Inogen (INGN), MSA Safety (MSA), Wright Medical Group (WMGI), Halyard Health (HYH), Invacare (IVC), CONSORT Med PLC/S (CSRMY), Sientra (SIEN) and RTI Surgical (RTIX).

News stories about EW stock have been trending somewhat negative recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edwards Lifesciences earned a media sentiment score of -0.02 on Accern's scale. They also gave media coverage about the medical research company an impact score of 44.81 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Edwards Lifesciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.43%), American Century Companies Inc. (1.32%), Northern Trust Corp (1.13%), Wells Fargo & Company MN (1.06%), Disciplined Growth Investors Inc. MN (0.98%) and Massachusetts Financial Services Co. MA (0.97%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, Jean-Luc M Lemercier, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., WCM Investment Management CA, Sei Investments Co., Blair William & Co. IL, DekaBank Deutsche Girozentrale, Envestnet Asset Management Inc., Schroder Investment Management Group and Swiss National Bank. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

EW stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., BlackRock Inc., OppenheimerFunds Inc., Rockefeller Capital Management L.P., Royal Bank of Canada, Chicago Capital LLC, Prudential Financial Inc. and Country Trust Bank. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo and Kieran Gallahue. View Insider Buying and Selling for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EW stock can currently be purchased for approximately $152.87.

Edwards Lifesciences has a market capitalization of $32.08 billion and generates $3.44 billion in revenue each year. The medical research company earns $583.60 million in net income (profit) each year or $3.80 on an earnings per share basis. Edwards Lifesciences employs 12,200 workers across the globe.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]